Perclose device successful in first human trial:
This article was originally published in Clinica
Executive Summary
Perclose claims that initial human clinical testing of its automated device for suturing blood vessels during conventional or minimally invasive coronary artery bypass surgery has shown promising results. The Menlo Park, California-based company said that by automating the delivery of 10 needles and sutures to the coronary artery and saphenous vein, its Heartflo system provided a precise, consistent and repeatable suture pattern. An automated suturing approach is expected to be particularly important during minimally invasive cardiac surgery where surgeons have to work through small incisions in the chest, often on a beating heart.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.